Triple-negative cancers showed the highest expression of IGKC (median 35.76; interquartile range [IQR] 33.89–37.52) followed by HER2-positive tumors (median 35.07; IQR 33.73–36.82) and luminal cancers (median 34.29; IQR 33.05–35.58) (Figure 2). This evidence concerns the gene IGKC and cancer.